MX9202804A - Composicion farmaceutica y terapeutica que comprende una nueva molecula de adhesion intracelular. - Google Patents

Composicion farmaceutica y terapeutica que comprende una nueva molecula de adhesion intracelular.

Info

Publication number
MX9202804A
MX9202804A MX9202804A MX9202804A MX9202804A MX 9202804 A MX9202804 A MX 9202804A MX 9202804 A MX9202804 A MX 9202804A MX 9202804 A MX9202804 A MX 9202804A MX 9202804 A MX9202804 A MX 9202804A
Authority
MX
Mexico
Prior art keywords
molecula
pharmaceutical
new
therapeutic composition
intracellular adhesion
Prior art date
Application number
MX9202804A
Other languages
English (en)
Spanish (es)
Inventor
Antonin R Defougerolles
Timothy A Springer
Original Assignee
Blood Res Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blood Res Center filed Critical Blood Res Center
Publication of MX9202804A publication Critical patent/MX9202804A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70525ICAM molecules, e.g. CD50, CD54, CD102
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX9202804A 1991-06-11 1992-06-11 Composicion farmaceutica y terapeutica que comprende una nueva molecula de adhesion intracelular. MX9202804A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71287991A 1991-06-11 1991-06-11

Publications (1)

Publication Number Publication Date
MX9202804A true MX9202804A (es) 1992-12-01

Family

ID=24863928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9202804A MX9202804A (es) 1991-06-11 1992-06-11 Composicion farmaceutica y terapeutica que comprende una nueva molecula de adhesion intracelular.

Country Status (21)

Country Link
EP (1) EP0590051A4 (fi)
JP (1) JP3288042B2 (fi)
KR (2) KR100333120B1 (fi)
CN (1) CN1188528C (fi)
BG (1) BG61682B1 (fi)
BR (1) BR9206142A (fi)
CA (1) CA2110387A1 (fi)
CZ (1) CZ283478B6 (fi)
FI (1) FI935500A (fi)
HU (1) HU217176B (fi)
IE (1) IE921893A1 (fi)
IL (1) IL102176A (fi)
MX (1) MX9202804A (fi)
NO (1) NO317658B1 (fi)
NZ (1) NZ243114A (fi)
RO (1) RO115415B1 (fi)
RU (1) RU2130782C1 (fi)
SK (1) SK279937B6 (fi)
UA (1) UA27763C2 (fi)
WO (1) WO1992022323A1 (fi)
ZA (1) ZA924276B (fi)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891841A (en) * 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
US5773218A (en) * 1992-01-27 1998-06-30 Icos Corporation Method to identify compounds which modulate ICAM-related protein interactions
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
JP3616090B2 (ja) * 1992-01-27 2005-02-02 イコス コーポレイション 細胞間接着分子関連タンパク質
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
WO1999018441A1 (en) * 1992-01-27 1999-04-15 Icos Corporation Icam-4 and diagnostic uses thereof
US5702917A (en) * 1992-01-27 1997-12-30 Icos Corporation Polynucleotides encoding human ICAM-4
CA2132637A1 (en) * 1993-01-22 1994-08-04 Michael W. Gallatin Icam-related protein
US6027922A (en) * 1993-11-02 2000-02-22 Innogenetics N.V. Human foam cells and methods for preparing them, monoclonal antibodies to said foam cells and their pharmaceutical and diagnostic use
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
EP0956508B1 (en) * 1997-10-02 2003-04-09 Icos Corporation Icam-4 and diagnostic uses thereof
CZ2002518A3 (cs) 1999-08-13 2002-05-15 Biogen, Inc. Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US7691591B2 (en) * 2002-09-20 2010-04-06 Stichting Katholieke Universiteit Methods of identifying and isolating cells expressing DC-sign
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
EP2041299A4 (en) 2006-07-14 2010-01-13 Aviva Biosciences Corp METHOD AND COMPOSITIONS FOR DETECTION OF RARE CELLS FROM A BIOLOGICAL SAMPLE
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
WO2014160883A1 (en) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Treating fibrosis and inflammation by inhibiting tl1a
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097747T3 (es) * 1989-03-09 1997-04-16 Blood Res Center Molecula de adhesion intercelular 2 y sus ligandos de union.

Also Published As

Publication number Publication date
AU2237692A (en) 1993-01-12
ZA924276B (en) 1993-03-31
CZ283478B6 (cs) 1998-04-15
NO934491D0 (no) 1993-12-09
HU217176B (hu) 1999-12-28
NZ243114A (en) 1995-03-28
NO317658B1 (no) 2004-11-29
SK139593A3 (en) 1994-10-05
CN1188528C (zh) 2005-02-09
EP0590051A1 (en) 1994-04-06
KR100333120B1 (ko) 2002-04-18
KR100291844B1 (ko) 2001-09-17
JPH06509706A (ja) 1994-11-02
FI935500A (fi) 1994-02-09
CA2110387A1 (en) 1992-12-23
NO934491L (no) 1994-02-11
HUT66617A (en) 1994-12-28
HU9303529D0 (en) 1994-04-28
SK279937B6 (sk) 1999-06-11
BR9206142A (pt) 1994-12-27
BG98287A (bg) 1994-08-30
JP3288042B2 (ja) 2002-06-04
BG61682B1 (bg) 1998-03-31
RU2130782C1 (ru) 1999-05-27
IE921893A1 (en) 1992-12-16
RO115415B1 (ro) 2000-02-28
CZ270293A3 (en) 1994-08-17
UA27763C2 (uk) 2000-10-16
WO1992022323A1 (en) 1992-12-23
FI935500A0 (fi) 1993-12-08
AU670243B2 (en) 1996-07-11
CN1069522A (zh) 1993-03-03
EP0590051A4 (en) 1994-10-12
IL102176A0 (en) 1993-01-14
IL102176A (en) 2001-09-13

Similar Documents

Publication Publication Date Title
MX9202804A (es) Composicion farmaceutica y terapeutica que comprende una nueva molecula de adhesion intracelular.
DK0754061T3 (da) Ny oral farmaceutisk doseringsform
ATA129892A (de) Pharmazeutische zusammensetzung
DE69618587T2 (de) Chinazoline und pharmazeutische zusammensetzungen
MX9202934A (es) Derivados de carbostirilo y composicion farmaceutica que los contiene.
BR1100824A (pt) Composto e composição farmacêutica
DE10199066I1 (de) Pharmazeutische Zusammensetzung
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
DE69525148D1 (de) Pharmazeutische formulierung
BR1100329A (pt) Composto e formulação farmacêutica
FI955681A0 (fi) Masennuslääkkeen annostusmuoto
DE69634053D1 (de) Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
IS1981B (is) Nýtt form S-handhverfu ómeprasóls og lyfjablöndursem innihalda það
FI954767A (fi) Lipofiilisiä lääkeaineita sisältävä farmaseuttinen koostumus
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
DE69300913D1 (de) Polymorph Terazosin und pharmazeutische Zusammenstellung.
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
DE4294862T1 (de) Pharmazeutische Komposition
MA22490A1 (fr) Composition insecticide et unite insecticide
MX9202763A (es) Nuevos derivados de 2-(1-piperazinil)-4-fenil-cicloalcanopiridina y composicion farmaceutica que los contiene.
DE69614407T2 (de) Pharmazeutische zusammensetzungen
FI973229A (fi) Uusi farmaseuttinen koostumus
ATE256465T1 (de) Orale arzneimittel zubereitung von piperdinoalkanole in gelöster form
FI964113A (fi) Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö
FI973230A (fi) Uusi farmaseuttinen formulaatio

Legal Events

Date Code Title Description
FA Abandonment or withdrawal